HeartWare International — Technical Presentation (April 2009)
19 slides from HeartWare International's technical presentation, Apr 24, 2009
Slide 1: Clinical Results of the International HeartWare Ventricular Assist System Bridge to Transplant Trial
Clinical Results of the International HeartWare(r) Ventricular Assist System Bridge to Transplant Trial M. Strueber, A. Khaghani, P. Jansz, G. O^Driscoll and G. Wieselthaler
Slide 2: The HeartWare Ventricular Assist System HVAD
The HeartWare(r) Ventricular Assist System HVAD(tm) miniaturized implantable blood pump 50cc / 140g, 50mm outside diameter 10 liters of flow Advanced Impeller is the only moving part Hybrid magnetic / hydrodynamic Wear-less system Two motors designed to provide power redundancy Thin (4.2 mm), flexib
Slide 3: HeartWare Peripheral Equipment
HeartWare Peripheral Equipment Controller with LCD display, audible alarms and 30 day data storage 2 small, Lithium ION Batteries last12 hours Touch screen Hospital Monitor with pump parameters & flow waveforms
Slide 4: Pericardial Placement - a Key Advantage
Pericardial Placement - a Key Advantage Low blood loss Potential for short CPB implant time No abdominal surgery No pump pocket 3 step implant technique
Slide 5: First Human Clinical Trial Overview
First Human Clinical Trial Overview First human trial of HVAD(tm) Pump also served as CE mark study Primary endpoint is survival to transplantation, on the device, or explanted to recovery at 180 days Secondary study endpoints include: Pre-implant cardiac index vs. pump index Incidence of all report
Slide 6: International HeartWare BTT Trial Centers
International HeartWare BTT Trial Centers # Patients Harefield Hospital, UK 3 Asghar Khaghani, Emma Birks Royal Perth Hospital, Australia 8 Gerry O'Driscoll, Rob Larbalestier, Lawrence Dembo St. Vincent's Hospital, Australia 10 Paul Jansz, Philip Spratt Vienna General Hospital, Austria 10 Georg Wies
Slide 7: Competing Outcomes (n = 50)
Competing Outcomes (n = 50) 90% 46% 32% 16% 6% 84% 84% 86% Months from Implant % of Patients Survival to 180 days, Transplant, Recovery Transplant Recovery Death Alive on Pump
Slide 8: Patient Demographics (n=50)
General: Age: 48.5 + 13.6 years BSA: 1.51 to 2.56 m2 (mean 1.97 m2) Weight: 78.4 + 18 kg Patient Demographics (n=50) Gender Distribution Etiology
Slide 9: Preoperative Hemodynamics (n = 50)
Preoperative Hemodynamics (n = 50) Parameter HeartWare HM II* Cardiac Index (L/min/m2) 1.94 +- 0.54 2.0 +- 0.6 LVEF (%) 18.7 +- 5.9 16.3 +- 5.7 BP Systolic (mmHg) 101.5 +- 13.9 95.8 +- 14.6 BP Diastolic (mmHg) 64.2 +- 10.9 61.7 +- 11.3 Mean BP (mmHg) 76.7 +- 10.6 73 PCWP (mmHg) 23.7 +- 6.5 26.1 +- 7
Slide 10: Clinical Trial Highlights (n = 50)
Data cut-off February 25, 2009. Clinical Trial Highlights (n = 50) Overall survival at 180 days 90% Total duration of pump support 41.1 years Average pump support 300 days Average days on pump at time of transplant 294 days Patients transplanted at 180 days 14% Six month survival after transplant 94
Slide 11: Device Performance Highlights (n = 50)
Device Performance Highlights (n = 50) Successful pericardial placements 100% Reduction in re-hospitalizations post implants* 80% Average pump flow and power 6.2 L 4.8 w Recorded single Battery support time 6 hrs Peri-operative survival 96% Shortest cardiac bypass time 21 min Mechanical pump failure
Slide 12: Spring 2007 Device Impeller Issue
Spring 2007 Device Impeller Issue Pump thrombus and high AE rates in 6 patients Diagnosis pointed towards distorted thrust bearings Revised manufacturing processes and testing New devices began shipping in June 2007 No reoccurrences Bearing Shroud
Slide 13: Serious Adverse Events
Serious Adverse Events Event Event Rate per Patient Year Event Rate per Patient Year Event Rate per Patient Year Event n=6 w/ MFG defect n=44 n=50 All infection 0.78 0. 39 0.44 Bleeding requiring operation (% of patients) 0.39 (33%) 0.17 (14%) 0.19 (16%) Respiratory dysfunction 0.39 0.19 0.22 Right
Slide 14: Device Exchanges
Device Exchanges 4 exchanges (excluding 2 exchanges from impeller manufacturing issue) Reasons: Ingest pre-implant LV thrombus: 1 RVAD flow and mitral apparatus occlusion: 1 Ingest LV thrombus: 2 (patients not on anti-platelet therapy) All were exchanged to a second HVAD(tm) Pump
Slide 15: All Neurologic Events (n = 50)
All Neurologic Events (n = 50) Neurological Event # Patients (%) Event Rate (per patient year) Ischemic CVA (2) 2 (4%) 0.05 TIA (1) /PRIND (2) 2 (4%) 0.07 Hemorrhagic CVA (2) 2 (4%) 0.05
Slide 16: Summary of Deaths (n = 50)
Summary of Deaths (n = 50) Cause Number of Patients Multi-organ failure 6* Hemorrhagic stroke 1 *3 deaths prior to discharge
Slide 17: Quality of Life is Significantly Improved
Quality of Life is Significantly Improved Kansas City Cardiomyopathy Questionnaire Symptom burden Physical Limitations Overall Improvement Quality of Life Time Time Time Time
Slide 18: Neurocognitive Evaluation (n = 44)
Neurocognitive Evaluation (n = 44)
Slide 19: Conclusions From First BTT Trial
Conclusions From First BTT Trial Promising results with 90% survival at 180 days in first human study Successful implant in the pericardial space without surgical pump pocket Patient implant days unusually long for a BTT trial without adversely impacting AE rates Excellent survival post transplantat
HeartWare International — Technical Presentation (April 2009) on 6ix